CHRNA5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1422941	1.00	5/20
SCHEMBL1423067	0.64	5/20
SCHEMBL1423125	0.64	5/20
Hydrochloric Acid (SCHEMBL1422679)	0.62	5/20
SCHEMBL1422804	0.61	5/20
SCHEMBL1423161	0.61	5/20
SCHEMBL1422499	0.58	5/20
SCHEMBL1423560	0.58	5/20
SCHEMBL1423437	0.57	5/20
SCHEMBL1421777	1.00	4/20
SCHEMBL1423102	1.00	4/20
SCHEMBL1422881	0.90	4/20
SCHEMBL1422532	0.78	4/20
SCHEMBL1422542	0.78	4/20
SCHEMBL1423089	0.78	4/20
SCHEMBL1423251	0.78	4/20
SCHEMBL1423254	0.78	4/20
SCHEMBL1422554	0.76	4/20
SCHEMBL1423294	0.73	4/20
SCHEMBL1422717	0.73	4/20

Clinical trials — most relevant to CHRNA5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)	PHASE4	COMPLETED
Galantamine for Cognition in People With Schizophrenia	PHASE4	COMPLETED
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia	PHASE4	COMPLETED
Postoperative Sugammadex After COVID-19	PHASE4	UNKNOWN
The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease	PHASE4	COMPLETED
Transcranial Magnetic Stimulation in Patients with Dual Disorders	PHASE3	NOT_YET_RECRUITING
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3	PHASE2	COMPLETED
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])	PHASE2	COMPLETED
Nicotinic Receptors and Schizophrenia	PHASE1/PHASE2	WITHDRAWN
Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes	PHASE2	COMPLETED
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Varenicline (Chantix™) for the Treatment of Alcohol Dependence	PHASE2	COMPLETED
Nicotinic Receptor Genetic Variation and Alcohol Reward	PHASE1	RECRUITING
Brain Networks and Addiction Susceptibility	PHASE1	COMPLETED
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine	PHASE1	WITHDRAWN
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals	PHASE1	COMPLETED
Sensitivity to Intravenous Nicotine: Genetic Moderators	PHASE1	COMPLETED
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression	nan	COMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia	nan	COMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine	nan	WITHDRAWN
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia	nan	COMPLETED
Brain Imaging in Alzheimer's Disease	nan	COMPLETED
Nicotinic Receptor Levels After Stopping Smoking	nan	COMPLETED
The Locus Coeruleus, Norepinephrine and Cognitive Aging	nan	ACTIVE_NOT_RECRUITING
Cognitive Effects of Mint Essential Oil	nan	COMPLETED
Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers	nan	COMPLETED
PET Imaging of Nicotinic Acetylcholine Receptors	nan	COMPLETED
Non-Invasive Brain Stimulation to Improve Language in Down Syndrome.	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CHRNA5 binder may also engage these)

Protein	Name	Similarity
Q5IS51	—	1.000	Q5IS51 →
Q8R4G9	—	1.000	Q8R4G9 →
P20420	—	1.000	P20420 →
Q2MKA5	—	1.000	Q2MKA5 →
Q07263	—	1.000	Q07263 →
P18257	—	1.000	P18257 →
P49581	—	1.000	P49581 →
P04756	—	1.000	P04756 →
P02711	—	1.000	P02711 →
P26152	—	1.000	P26152 →
P02709	—	1.000	P02709 →
Q8SPU7	—	1.000	Q8SPU7 →
Q5IS75	—	0.999	Q5IS75 →
CHRNB3	Neuronal acetylcholine receptor subunit beta-	0.999	landscape →
P12391	—	0.999	P12391 →
P43679	—	0.998	P43679 →
P25108	—	0.997	P25108 →
P43143	—	0.997	P43143 →
Q27218	—	0.997	Q27218 →
O16926	—	0.997	O16926 →
CHRNA6	Neuronal acetylcholine receptor subunit alpha	0.997	landscape →
Q9U298	—	0.997	Q9U298 →
P13908	—	0.996	P13908 →
P02710	—	0.996	P02710 →
P05377	—	0.995	P05377 →
Q23022	—	0.994	Q23022 →
CHRNA1	Acetylcholine receptor subunit alpha	0.994	landscape →
P04757	—	0.994	P04757 →
Q93149	—	0.993	Q93149 →
P09484	—	0.993	P09484 →